Entereg’s REMS To Assess Off-Label Use In Quarterly Reports To FDA

Adolor will monitor off-label use of Entereg (alvimopan) under the Risk Evaluation and Mitigation Strategy for the postoperative constipation therapy, but the firm is silent on how it will handle situations of non-compliance with the drug's required controlled distribution system

More from Archive

More from Pink Sheet